secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001178913-26-001792
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio FY2025 net loss $11.4M, cash runway to mid-Q3 2026; EB613 Phase 3 submitted
--------------------------------------------------------------------------------

- Net loss $11.4M ($0.25/sh) vs $9.5M in FY2024; R&D expenses $6.0M up from $4.5M.
- Cash $14.9M at Dec 31, 2025 incl. $7.8M restricted for OPKO collab; operating cash burn $7.4M.
- EB613 Phase 3 protocol submitted Mar 2026; FDA feedback expected late Apr 2026 with topline in H2 2028.
- EB612 (LA-PTH) collaboration with OPKO expanded; IND filing expected late 2026.
- EB618 (oral OXM) PK/PD validation complete; Phase 1 initiation dependent on injectable data by YE 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326001792/0001178913-26-001792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326001792/zk2634965.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-001792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer